摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9'-amino-10'-fluoro-2',3'-dihydro-2'-methyl-8'-oxo-11'-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4'-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7'-carboxylc acid | 1132813-48-9

中文名称
——
中文别名
——
英文名称
9'-amino-10'-fluoro-2',3'-dihydro-2'-methyl-8'-oxo-11'-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4'-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7'-carboxylc acid
英文别名
9'-amino-10'-fluoro-2',3'-dihydro-2'-methyl-8'-oxo-11'-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4'-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7'-carboxylic acid;6-Amino-7-fluoro-11-methyl-4-oxo-8-[2-(pyridin-2-ylamino)ethylamino]spiro[10-oxa-1-azatricyclo[7.4.1.05,14]tetradeca-2,5,7,9(14)-tetraene-13,1'-cyclobutane]-3-carboxylic acid
9'-amino-10'-fluoro-2',3'-dihydro-2'-methyl-8'-oxo-11'-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4'-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7'-carboxylc acid化学式
CAS
1132813-48-9
化学式
C24H26FN5O4
mdl
——
分子量
467.5
InChiKey
KOFKPLUCMPXZKA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    34
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    130
  • 氢给体数:
    4
  • 氢受体数:
    10

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    ethyl 3-ethoxy-2-(2,3,4,5-tetrafluorobenzoyl)acrylate 在 硫酸 、 palladium 10% on activated carbon 、 氢气 、 sodium hydride 、 potassium nitrate三乙胺 、 sodium hydroxide 作用下, 以 乙醇二甲基亚砜N,N-二甲基甲酰胺甲苯 为溶剂, 120.0 ℃ 、101.33 kPa 条件下, 反应 18.0h, 生成 9'-amino-10'-fluoro-2',3'-dihydro-2'-methyl-8'-oxo-11'-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4'-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7'-carboxylc acid
    参考文献:
    名称:
    Quinolone derivatives containing strained spirocycle as orally active glycogen synthase kinase 3β (GSK-3β) inhibitors for type 2 diabetics
    摘要:
    The design, synthesis, and evaluation of 6-6-7 tricyclic quinolones containing the strained spirocycle moiety aiming at the GSK-3 beta inhibitor were described. Among the synthesized compounds, 44, having a cyclobutane ring on a spirocycle, showed excellent GSK-3b inhibitory activity in both cell-free and cell-based assays (IC50 = 36 nM, EC50 = 3.2 mu M, respectively). Additionally, 44 decreased the plasma glucose concentration dose-dependently after an oral glucose tolerance test in mice. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2011.12.046
点击查看最新优质反应信息

文献信息

  • [EN] SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS<br/>[FR] AMINOQUINOLONES SPIROCYCLIQUES UTILISÉES EN TANT QU'INHIBITEURS DE GSK-3
    申请人:ACTIVX BIOSCIENCES INC
    公开号:WO2009035684A1
    公开(公告)日:2009-03-19
    Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK- 3 inhibitors mediated diseases. In Formula (I): X1 is O or NR8; A is bond or substituted or unsubstituted C1-C2 alkylene, wherein the substituents when present are selected from one to four Q2 groups; where Q2 is alkyl or haloalkyl; p is 0 or 1; and q is an integer of 0 to 2.
    本文提供了化学式I的螺环氨基喹啉类化合物和含有这些化合物的组合物。本文提供的化合物和组合物可用于预防、改善或治疗GSK-3抑制剂介导的疾病。在化学式(I)中:X1为O或NR8;A为键或取代或未取代的C1-C2烷基,其中取代基在存在时来自于一个到四个Q2基团;其中Q2为烷基或卤代烷基;p为0或1;q为0到2的整数。
  • SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS
    申请人:Cociorva Oana
    公开号:US20110034436A1
    公开(公告)日:2011-02-10
    Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases. In Formula (I): X 1 is O or NR 8 ; A is bond or substituted or unsubstituted C 1 -C 2 alkylene, wherein the substituents when present are selected from one to four Q 2 groups; where Q 2 is alkyl or haloalkyl; p is 0 or 1; and q is an integer of 0 to 2.
    本文提供了公式I的螺环氨基喹啉酮和含有该化合物的组合物。本文提供的化合物和组合物在预防、改善或治疗GSK-3抑制剂介导的疾病方面具有用途。在公式(I)中:X1为O或NR8;A为键或取代或未取代的C1-C2烷基,其中取代基在存在时从1到4个Q2基中选择;其中Q2为烷基或卤代烷基;p为0或1;q为0到2的整数。
  • EP2203459B1
    申请人:——
    公开号:EP2203459B1
    公开(公告)日:2016-03-16
  • US8476261B2
    申请人:——
    公开号:US8476261B2
    公开(公告)日:2013-07-02
  • US8901112B2
    申请人:——
    公开号:US8901112B2
    公开(公告)日:2014-12-02
查看更多